Powered by ALPHA META AI's proprietary technology, evidaeo.ai helps brands strengthen visibility and credibility across leading AI platforms, languages, and markets.
Lincoln's Double Explores Faith, Forgiveness, and Providence Amidst the Civil War
A Family Story Sparks a Riveting Historical Novel of a Confederate Soldier, Abraham Lincoln, and an Unexpected Friendship
A Journey of Deception, Faith, and the Search for Redemption
Drawing on 45 years of consulting experience, Montgomery's new books walk small business owners through hiring, oversight, and fraud recognition
How Mark Lehman's Power Access Control Scaled to an $8–$10M Empire
AI governance keynote speaker and human-centric futurist recognised for teaching 162,000+ leaders to govern technology with human judgment ZUG, SWITZERLAND, October 25, 2026 / EINPresswire.com / -- Dr. Martha Boeckenfeld, a human-centric futurist and keynote speaker on artificial intelligence (AI) governance, has been named Tech Influencer of the Year at the Influencer Magazine Awards 2026. The award recognises her w
LONDON, UNITED KINGDOM, October 25, 2026 / EINPresswire.com / -- Prof. Dr. Shabnam (Shery) Delfani, internationally recognised environmental scientist, professor and geopolitical analyst, has been awarded the International Recognition Award at the Influencer Magazine Awards (E3) on October 25, 2026, honouring her extraordinary contributions to climate change modelling, sustainability, water diplomacy and internationa
Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor … Continue reading "Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer"
In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses 75% (18/24) disease control rate (DCR) … Continue reading "NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma"
Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmark Disease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to TRAEs Data informed FDA-aligned dose and regimen selection for upcoming PEDESTAL … Continue reading "Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors"
VANCOUVER, British Columbia, Oct. 24, 2026 — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) announced today that strike action by United Steelworkers (USW) Local 7619 has commenced at Teck's Highland Valley Copper (HVC) Operations in B.C. Operations are currently continuing at a reduced capacity. The impact on overall production will … Continue reading "Teck Provides Update on Highland Valley Copper Operations"